Actelion Pharmaceuticals Ltd

act-064992 - macitentan

 

Study ID Status Type Title
AC-055-302 Completed Results Summary A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of macitentan (ACT-064992) on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension
AC-055B201 Completed Results Summary A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis
AC-055C301 Completed Results Summary Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers associated with systemic sclerosis
AC-055C302 Completed Results Summary Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers associated with systemic sclerosis
AC-055E201 Completed Results Summary Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension